Immix Biopharma On Track To Dose NXC-201 U.S. Patients
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma is on schedule for U.S. site initiation visits in April and May 2024, aiming to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at its New York City lead site and other leading U.S. sites by mid-2024. There is no change in the timing of patient enrollment.
April 18, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma is progressing as planned with its U.S. site initiation for dosing AL Amyloidosis patients with CAR-T NXC-201, indicating a positive development in its clinical trials.
The news indicates a positive development in Immix Biopharma's clinical trial process for NXC-201, suggesting potential for future success and regulatory approvals. This progress could positively influence investor sentiment and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100